A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 ...
Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...
Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback